Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Infectivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Infectivity. Displaying page 1 of 1.
    EudraCT Number: 2021-005229-26 Sponsor Protocol Number: RIFT-HPV Start Date*: 2022-03-09
    Sponsor Name:Dr. Miguel Angel Pavón Ribas
    Full Title: A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women Before and After Vaccination with 9vHPV, a Mul...
    Medical condition: Human Papillomavirus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003710-84 Sponsor Protocol Number: CIIS Start Date*: 2014-11-27
    Sponsor Name:Imperial College London
    Full Title: The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.
    Medical condition: Human Immunodificiency Virus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001282-24 Sponsor Protocol Number: REVCS002 Start Date*: 2017-06-21
    Sponsor Name:ReViral Ltd
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of RV521 Against Respiratory Syncytial Virus infecti...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005239-80 Sponsor Protocol Number: 10007 Start Date*: 2005-12-23
    Sponsor Name:University Hospitals Leicester, Leicester General Hospital
    Full Title: Prospective study to assess the emergence of drug resistance to oseltamivir following treatment of acute influenza A among children
    Medical condition: Influenza A
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002723-16 Sponsor Protocol Number: PREMIVER Start Date*: 2018-04-20
    Sponsor Name:Universitaetsklinikum Tuebingen
    Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial
    Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014....
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012876-29 Sponsor Protocol Number: 10762 Start Date*: 2009-07-07
    Sponsor Name:University Hospitals Leicester
    Full Title: A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004994-27 Sponsor Protocol Number: 2020SW03 Start Date*: 2020-12-16
    Sponsor Name:Ashford and St Peter's Hospitals NHS Foundation Trust
    Full Title: Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005929-49 Sponsor Protocol Number: VX11-787-101 Start Date*: 2012-02-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001538-28 Sponsor Protocol Number: P130930 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10070264 Measles virus test positive LLT
    Population Age: Newborns, Under 18, Adults Gender: Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001718-31 Sponsor Protocol Number: VAC063 Start Date*: 2016-08-24
    Sponsor Name:University of Oxford, CTRG
    Full Title: A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/AS01
    Medical condition: Plasmodium falciparum malaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000504-42 Sponsor Protocol Number: ABT-003 Start Date*: 2019-05-21
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease
    Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003746-33 Sponsor Protocol Number: REVC006 Start Date*: 2020-09-30
    Sponsor Name:ReViral Ltd.
    Full Title: Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) ...
    Medical condition: Symptomatic RSV infection (upper airway involvement only) in subjects who have undergone HCT transplantation within 1 year of Randomization and who are moderately to severely immunocompromised.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10024970 Respiratory tract infections HLGT
    21.1 10021881 - Infections and infestations 10024968 Lower respiratory tract infection PT
    20.1 10021881 - Infections and infestations 10065188 Lower respiratory tract infection viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001010-15 Sponsor Protocol Number: REVC003 Start Date*: 2019-10-24
    Sponsor Name:ReViral Ltd.
    Full Title: A Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability,...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001103-31 Sponsor Protocol Number: AIT02-2001/DMID14-005 Start Date*: 2015-07-10
    Sponsor Name:Autoimmune Technologies, LLC
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh...
    Medical condition: Influenza A infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002213-18 Sponsor Protocol Number: EDP938-103 Start Date*: 2020-11-05
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection o...
    Medical condition: Respiratory syncytial virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001411-39 Sponsor Protocol Number: ABT-002 Start Date*: 2018-09-04
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-002215-29 Sponsor Protocol Number: EDP938-104 Start Date*: 2023-02-03
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at ...
    Medical condition: Respiratory syncytial virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004645-32 Sponsor Protocol Number: FLT190-02 Start Date*: 2020-03-24
    Sponsor Name:Freeline Therapeutics Ltd
    Full Title: A Multicentre, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:08:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA